ArticleFrontiers in psychiatry2025
Psychological correlates of performance-enhancing drug use: Emotional, cognitive, and social functioning in long-term and short-term users.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Performance-enhancing drug (PED) use-particularly anabolic-androgenic steroids (AAS)-has expanded from competitive sport into mainstream fitness settings. Although PED use is associated with emotional, cognitive, and social difficulties, less is known about how duration of use or psychosocial factors shape these outcomes. Understanding these dynamics is essential for identifying individuals at greater risk for psychological impairment. Methods: A total of 285 adult gym-goers (87 long-term users, 95 short-term users, 103 non-users) completed validated measures of depression (BDI-II), anxiety (BAI), muscle dysmorphia (MDDI), self-efficacy (GSE), social support (MSPSS), and social functioning (SASS), along with the Stroop test assessing executive function. Group comparisons, multiple regressions, and PROCESS-based mediation and moderation analyses were conducted, controlling for demographic covariates. Results: Long-term PED users reported significantly higher depression, anxiety, and muscle dysmorphia than short-term users and non-users, and showed poorer Stroop interference performance. Mediation analysis revealed that depression and anxiety partially explained the link between PED use and poorer social functioning. Moderation results indicated that stronger self-efficacy and higher perceived social support buffered depressive and anxious symptoms among users. Discussion: Chronic PED use is associated with heightened emotional distress and reduced executive functioning, which in turn contribute to impaired social functioning. However, psychosocial resources such as self-efficacy and social support may mitigate these adverse effects. These findings underscore the need for routine psychological assessment and the development of supportive, prevention-oriented interventions for individuals engaged in PED use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.